PATH DC Office, 455 Massachusetts Ave NW, 20001, Washington, DC, USA.
PATH, 2201 Westlake Ave Suite 200, Seattle, 98121, WA, USA.
Best Pract Res Clin Obstet Gynaecol. 2020 Jul;66:95-106. doi: 10.1016/j.bpobgyn.2020.01.003. Epub 2020 Jan 23.
As new reproductive health products become available, women increasingly want to take a participatory role in their health. New developments and formulations of contraceptive products provide an opportunity to support this evolving trend toward self-care. Self-care, as defined by the World Health Organization (WHO), highlights the ability of individuals to promote health, prevent disease, and manage their own health with or without the support of a health care provider. The recently released WHO Guidelines on Self-Care Interventions for Health: Sexual and Reproductive Health and Rights included new self-care recommendations related to use of family planning, including self-injection of injectable contraceptives and over-the-counter provision of oral contraceptive pills. This paper focuses on the research evidence of self-administration (self-injection) of subcutaneous depot medroxyprogesterone acetate (DMPA-SC), and the practical experience of providers, women, and family planning programs adopting self-injection practices. We also explore the role of self-care in the provision of other contraceptives.
随着新的生殖健康产品的出现,越来越多的女性希望在自己的健康问题上发挥参与作用。避孕产品的新发展和新配方为支持这种朝着自我护理方向发展的趋势提供了机会。世界卫生组织(WHO)将自我护理定义为个人促进健康、预防疾病以及在没有或有医疗保健提供者支持的情况下管理自己健康的能力。最近发布的《世卫组织关于促进健康的自我护理干预措施指南:性健康和生殖健康及权利》包括了与计划生育使用相关的新的自我护理建议,包括自行注射避孕针和非处方提供口服避孕药。本文重点介绍皮下注射醋酸甲羟孕酮(DMPA-SC)的自我管理(自我注射)的研究证据,以及提供者、妇女和计划生育项目采用自我注射实践的实际经验。我们还探讨了自我护理在提供其他避孕药具方面的作用。